Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the rapidly evolving world of CAR T cell therapy, a groundbreaking treatment for various hematologic malignancies. Joined by experts Dr. Surbhi Sidana from Stanford University and Dr. Jason Westin from MD Anderson Cancer Center, we explore the mechanism of action of CAR T cells, their side effects, and management strategies.

Episode Highlights:

• Understanding CAR T cell therapy and its application in hematologic malignancies and solid tumors.
• Mechanism of action: How CAR T cells are engineered to target cancer cells.
• Acute side effects: Cytokine release syndrome (CRS) and neurotoxicity, including clinical pearls for management.
• Chronic side effects: Monitoring for infections, cytopenias, and the risk of secondary malignancies.
• The importance of bridging therapy and managing tumor burden before CAR T treatment.
• Insights for community oncologists on patient management and communication with CAR T centers.

Join us for an informative discussion that emphasizes the importance of recognizing and managing the unique side effects of CAR T therapy to ensure the best outcomes for patients. Don't forget to check out our other episodes for more insights into recent advances in hematology and oncology!

Subscribe for more discussions on FDA approvals, treatment algorithms, and conference highlights. We are the Oncology Brothers!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

Welcome back to the Oncology Brothers podcast! In this episode, we dive into the highlights from ASH 2024, focusing on key studies in leukemia. Join hosts Drs. Rahul and Rohit Gosain as they discuss groundbreaking research with Dr. Uma Borate from The Ohio State University.

Episode Highlights:
•⁠  ⁠KOMET 007 Study: An in-depth look at the Phase 1 study on the Menin inhibitor Ziftomenib, exploring its promising results in frontline settings for patients with NPM1 mutations and KMT2A rearrangements.
•⁠  ⁠CPX351 vs. 7+3 Induction: A discussion on the liposomal formulation CPX351 and its effectiveness compared to the traditional 7+3 induction therapy, particularly in patients with myelodysplasia-related AML.
•⁠  ⁠Venetoclax Combinations: Insights into the use of Venetoclax in combination with various therapies, including its role in treating patients without actionable mutations.

Key Takeaways:
•⁠  ⁠The importance of NGS testing in identifying targetable mutations in AML.
•⁠  ⁠Promising response rates and manageable toxicities associated with Menin inhibitors.
•⁠  ⁠The ongoing debate regarding the best induction therapy for AML patients.

Don't miss this informative discussion that sheds light on the evolving landscape of leukemia treatment!

Subscribe for more updates on oncology topics, including lymphoma, CLL, and myeloma discussions from ASH 2024. Thanks for tuning in! We are the Oncology Brothers.

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

In the second episode of a 4-part podcast series on HCC, the Oncology Brothers, Drs Rahul and Rohit Gosain, host a podcast discussion between Dr Lorenza Rimassa and Prof. Arndt Vogel on 2nd line treatment selection in advanced HCC and when to switch.

The discussion covers a range of topics, including 2nd line options for advanced HCC after progression on 1st line TKIs and IO-based therapies, as well as:

• How to approach sequencing in clinical practice
• The available data supporting sequencing strategies
• When to switch to 2nd line therapy and what to consider when doing so

This is the second video podcast episode in a 4-part series. Access the rest of the series here:

Part 1 - The use of IO in unresectable HCC

Part 3 - Intermediate HCC: treatment options and strategies (coming soon)

Part 4 - The evolving role of IO in intermediate HCC (coming soon)

Clinical takeaways

• Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions
• When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life.
• Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered
• Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management
• Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation.

Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

Welcome to another episode of the Oncology Brothers! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the complexities of managing side effects associated with antibody drug conjugates (ADCs). Joined by expert guests Dr. Tian Zhang, a GU medical oncologist from UT Southwestern, and Dr. Erika Hamilton from Sarah Cannon Research Institute, the discussion focuses on three key ADCs: Enfortumab vedotin, Sacituzumab govitecan, and Trastuzumab deruxtecan (TDXD).

Episode Highlights:
•⁠  ⁠Enfortumab vedotin: Learn about the common side effects such as skin toxicities, hyperglycemia, and neuropathy, and how to manage them effectively in clinical practice.
•⁠  ⁠Sacituzumab govitecan: Explore the challenges of neutropenia, diarrhea, and fatigue, and the importance of individualized patient care.
•⁠  ⁠Trastuzumab deruxtecan (TDXD): Understand the critical side effects including nausea, fatigue, and interstitial lung disease (ILD), and the strategies for prevention and management.

This episode emphasizes the importance of recognizing and acting on side effects that can significantly impact patient outcomes. Whether you're a healthcare professional or someone interested in oncology, this discussion will provide valuable insights into toxicity management for ADCs.

Don't forget to like, subscribe, and check out more episodes for in-depth discussions on oncology topics!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based combinations, along with emerging therapies and the latest clinical data.
 
Topics also include: 
• Efficacy and safety of IO and IO combinations in HCC
• How to select between the two 1st-line IO-based treatment options based on clinical factors
• Future treatment in unresectable HCC
 
Clinical Takeaways
• Two 1st-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape
• Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies
• Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen (single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up
• IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary
• In clinical practice, treatment choice should be individualised, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the recent FDA approval of Inavolisib for metastatic hormone receptor-positive breast cancer, based on the groundbreaking INAVO120 study.

Join us as we chat with Dr. Komal Jhaveri, a medical oncologist and senior author of the study from Memorial Sloan Kettering Cancer Center. We explored the study design, key findings, and the implications of this new treatment option for patients with PIK3CA mutations.

Key topics discussed include:
•⁠  ⁠Overview of the INAVO120 study and its significance
•⁠  ⁠The unique patient population targeted in the study
•⁠  ⁠Key findings, including the impressive improvement in progression-free survival (PFS)
•⁠  ⁠Side effects and management strategies for patients
•⁠  ⁠The importance of genetic testing in treatment decisions

Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment.

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#OncologyBrothers #BreastCancer #ENAVOLacib #PIK3CA #CancerResearch #MedicalPodcast #Oncology

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rohit and Rahul Gosain are joined by Dr. Eileen O'Reilly, a leading medical oncologist and section head of hepatobiliary and pancreatic cancer at Memorial Sloan Kettering Cancer Center. Together, they delve into the complex treatment landscape of pancreatic cancer.

Episode Highlights:

• ⁠ ⁠The initial workup for newly diagnosed pancreatic cancer patients, including the importance of imaging and genetic testing.
• ⁠ ⁠Treatment paradigms for early-stage, borderline resectable, and metastatic pancreatic cancer.
• ⁠ ⁠The role of multi-agent chemotherapy, including modified FOLFIRINOX and gemcitabine-nab-paclitaxel.
• ⁠ ⁠Insights into managing patients with high bilirubin levels and the considerations for dose adjustments.
• ⁠ ⁠The emerging role of targeted therapies and the significance of comprehensive genetic testing in treatment decisions.

Join us as we explore the latest standards of care, the importance of a multidisciplinary approach, and the potential of new therapies in improving outcomes for patients with pancreatic cancer.

Don't forget to like, subscribe, and check out our other episodes for more insights on oncology topics, conference highlights, and recent treatment approvals!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Neil Iyengar, a medical oncologist from Memorial Sloan Kettering Cancer Center, to discuss the critical role of nutrition and exercise in cancer care and recurrence prevention.
They tackle common questions from cancer survivors about lifestyle modifications that can help reduce the risk of cancer recurrence. With the current hype around various diets, the discussion delves into the evidence surrounding dietary patterns, exercise, and their impact on overall health and cancer outcomes.

Key topics included:
•⁠  ⁠The mixed evidence regarding diet and exercise in preventing cancer recurrence.
•⁠  ⁠The limitations of BMI as a measure of health and its implications in cancer studies.
•⁠  ⁠Insights from recent breast cancer trials on diet and survival rates.
•⁠  ⁠The importance of social determinants of health in dietary recommendations.
•⁠  ⁠Practical dietary guidelines and the significance of high-fiber, fruit-and-vegetable-rich diets.

Dr. Iyengar emphasized the need for ongoing research to provide more specific dietary recommendations for different cancer types and highlights resources available for patients and healthcare providers.

Join us for an informative discussion that aimed to empower cancer patients and healthcare professionals with knowledge about lifestyle interventions that can enhance quality of life and potentially improve cancer outcomes.

Don't forget to like, subscribe, and hit the notification bell for more insightful discussions from the Oncology Brothers!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

In this episode of the Oncology Brothers podcast, hosts Drs. Rohit and Rahul Gosain welcome Dr. Pamela Kunz, a world-renowned medical oncologist from the Yale Cancer Center, to discuss the complex landscape of neuroendocrine tumors (NETs).

Join us as we explore:
•⁠  ⁠The classification of neuroendocrine tumors based on grade, histological features, and the significance of KI-67.
•⁠  ⁠The role of imaging modalities, including Gallium PET-CT and its importance in evaluating disease extent.
•⁠  ⁠Treatment strategies for localized versus metastatic NETs, including the use of somatostatin analogs and the nuances of observation versus intervention.
•⁠  ⁠Insights into the latest treatment options, including lutetium dotatate, Capecitabine-Temozolomide, and the anticipated approval of Cabozantinib.
•⁠  ⁠The potential role of NGS testing and the challenges of combining chemotherapy with immunotherapy in high-grade neuroendocrine tumors.

Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the management of neuroendocrine tumors.

Don't forget to like, subscribe, and check out our other episodes for more discussions on current standard of care treatment options, conference highlights, and new drug approvals. We look forward to seeing you at GI ASCO in January 2025!

#OncologyBrothers #NeuroendocrineTumors #CancerCare #MedicalOncology #Podcast #NETs

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by esteemed palliative care experts Dr. Janet Abrahm from Dana-Farber Cancer Institute and Dr. Ishwaria Subbiah from Sarah Cannon Research Institute. Together, they delve into the critical topic of palliative care, exploring its evolution from a focus on end-of-life care to an integral part of cancer treatment that enhances both longevity and quality of life.

Key discussion points include:
•⁠  ⁠The definition and importance of palliative care as an "extra layer of support" for patients, families, and oncologists.
•⁠  ⁠The stigma surrounding palliative care and the potential benefits of rebranding it as supportive care.
•⁠  ⁠The significant impact of palliative care on symptom management and overall patient outcomes.
•⁠  ⁠Innovative approaches to integrating palliative care into oncology practices, including the use of technology and multidisciplinary teams.
•⁠  ⁠Effective communication strategies for discussing palliative care and advanced care planning with patients and their families.

Join us for this enlightening conversation that aims to demystify palliative care and highlight its essential role in cancer care. Don't forget to like, subscribe, and share your thoughts in the comments!
#OncologyBrothers #PalliativeCare #CancerCare #SupportiveCare #QualityOfLife #SymptomManagement #AdvancedCarePlanning

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain welcome Dr. Martina Murphy, an Associate Professor of Medicine and Senior Associate Dean of Graduate Medical Education at the University of Florida, to discuss the current landscape of ovarian cancer.

Join us as we dive into the critical aspects of diagnosing and managing ovarian cancer, including:
•⁠  ⁠The importance of surgical staging and primary debulking surgery
•⁠  ⁠The role of genetic testing, including BRCA and NGS, in treatment planning
•⁠  ⁠Adjuvant therapy options, focusing on platinum-based chemotherapy and the use of Bevacizumab
•⁠  ⁠Insights into PARP inhibitors and their application in BRCA-positive and wild-type patients
•⁠  ⁠Navigating treatment options for relapsed and refractory ovarian cancer, including the use of antibody-drug conjugates like Mirvetuximab and Trastuzumab Deruxtecan (TDXd).

Dr. Murphy shares her expertise on the latest advancements in ovarian cancer treatment, the significance of genetic testing, and the management of side effects associated with various therapies.

Tune in for a comprehensive overview of the standard of care for ovarian cancer and the evolving treatment landscape. Don't forget to check out our other episodes for more discussions on practice-changing data and current treatment options in oncology!

Subscribe to the Oncology Brothers podcast for more insights and updates in the field of oncology!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]